ABSTRACT
Finding a practical solution for effectively managing facility liquid biowaste is a process of deductive reasoning. Many considerations need to be addressed. The liquid effluent must be characterized to determine required capacity, materials of construction and mode of operation of the biowaste treatment system. Federal, state, local and corporate requirements must be identified to determine system operating parameters. Standard technologies can then be reviewed in order to select the most appropriate unit operation for processing the biowaste. Finally, a validation program is developed to demonstrate the efficacy of the treatment system's intended use. This presentation covers typical considerations in developing the design of a biowaste treatment system and validation of acceptance criteria. Several examples from industrial installations are presented.
Subject(s)
Medical Waste , Waste Disposal, Fluid/methods , Decontamination/instrumentation , Decontamination/methods , Equipment Design , United StatesABSTRACT
A new antitumor antibiotic, fredericamycin A (FCRC-A48, NSC-305263), has been isolated from a strain of Streptomyces griseus (FCRC-48). Based on its unique ultraviolet-visible spectrum, infrared spectrum, proton and carbon-13 nuclear magnetic resonance spectra and mass spectra, it is judged to be a novel acid-base indicator type of compound. Its production, isolation and physicochemical properties are discussed. The isolation, ultraviolet-visible spectrum and some biological properties of two minor components, fredericamycin B and fredericamycin C, are also described.
